Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 14/20 | 0.64 |
| ▸ | IKZF2 | Q9UKS7 | 6/20 | 0.55 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25230229 | 0.90 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| SCHEMBL30460119 | 0.90 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| SCHEMBL31116980 | 0.90 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| SCHEMBL25236602 | 0.90 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| SCHEMBL29450095 | 0.90 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| SCHEMBL25212437 | 0.90 | CRBN (0.60) | CRBNIKZF2IKZF1 | |
| Hydrochloric Acid SCHEMBL30496965 | 0.89 | CRBN (0.58) | CRBNIKZF2IKZF1 | |
| Hydrochloric Acid SCHEMBL25234527 | 0.89 | CRBN (0.58) | CRBNIKZF2IKZF1 | |
| SCHEMBL22557008 | 0.88 | CRBN (0.69) | CRBNIKZF2IKZF1 | |
| SCHEMBL29876913 | 0.88 | CRBN (0.69) | CRBNIKZF2IKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023177451-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF CYCLIN DEPENDENT KINASES | EnhancedBio Inc. (KR) | 2023-09-21 | — | — | WO | disclosed |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | ACCUTAR BIOTECHNOLOGY INC. (US) | 2022-01-11 | — | — | US | disclosed |
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | ACCUTAR BIOTECHNOLOGY INC. (US) | 2021-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210300901-A1 | NOVEL UREAS HAVING ANDROGEN RECEPTOR DEGRADATION ACTIVITY AND USES THEREOF | AR, UTS2R, ESRRA | CRBN 1041/4885IKZF2 4315/4885IKZF1 3057/4885 |
| US-11220490-B2 | Ureas having androgen receptor degradation activity and uses thereof | AR, UTS2R, ESRRA | CRBN 1098/4885IKZF2 4069/4885IKZF1 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.